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Abstract
Schistosomiasis affects millions of people in developing countries and is responsible for
more than 200,000 deaths annually. Because of toxicity and limited spectrum of activity of
alternatives, there is effectively only one drug, praziquantel, available for its treatment.
Recent data suggest that drug resistance could soon be a problem. There is therefore the
need to identify new drug targets and develop drugs for the treatment of schistosomiasis.
Analysis of the Schistosoma mansoni genome sequence for proteins involved in detoxifica-
tion processes found that it encodes a single cytochrome P450 (CYP450) gene. Here we
report that the 1452 bp open reading frame has a characteristic heme-binding region in its
catalytic domain with a conserved heme ligating cysteine, a hydrophobic leader sequence
present as the membrane interacting region, and overall structural conservation. The high-
est sequence identity to human CYP450s is 22%. Double stranded RNA (dsRNA) silencing
of S.mansoni (Sm)CYP450 in schistosomula results in worm death. Treating larval or adult
worms with antifungal azole CYP450 inhibitors results in worm death at low micromolar con-
centrations. In addition, combinations of SmCYP450-specific dsRNA and miconazole show
additive schistosomicidal effects supporting the hypothesis that SmCYP450 is the target of
miconazole. Treatment of developing S.mansoni eggs with miconazole results in a dose
dependent arrest in embryonic development. Our results indicate that SmCYP450 is essen-
tial for worm survival and egg development and validates it as a novel drug target. Prelimi-
nary structure-activity relationship suggests that the 1-(2,4-dichlorophenyl)-2-(1H-imidazol-
1-yl)ethan-1-ol moiety of miconazole is necessary for activity and that miconazole activity
and selectivity could be improved by rational drug design.
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Author Summary
Over 600 million people in endemic countries are at risk of contracting schistosomiasis,
which results in over 200,000 deaths each year and significant illness to most people that
are infected. There are concerns that the drug widely used for the treatment of schistoso-
miasis, praziquantel, may be losing efficacy due to evolution of drug resistant worms.
Since the disease mainly affects the poor in developing countries, pharmaceutical compa-
nies have little interest in developing new drugs and none are currently being tested. In
this paper we focus on a novel parasite protein, cytochrome P450, which we propose to be
a new drug target. Worms are unusual in having only one cytochrome P450 gene; humans
have 57 cytochrome P450 genes. By using reverse genetic and chemical approaches we
found that the schistosome cytochrome P450 is essential for worm survival and egg devel-
opment and, therefore, is an essential and druggable target. Drugs that target fungal cyto-
chrome P450s and are already in use for treating several human diseases were identified as
potential hits for further development for schistosomiasis treatment.
Introduction
Schistosomiasis is a helminthiasis caused by trematode worms of three main schistosome spe-
cies, Schistosoma mansoni, S. haematobium, and S. japonicum. The disease is responsible for
approximately 280,000 deaths annually and significant morbidity in more than 200 million
people [1,2]. Schistosomiasis belongs to a class of neglected tropical diseases whose control has
been given limited attention by the pharmaceutic industry because they affect poor people in
developing nations. Currently, praziquantel (PZQ) is the only treatment for schistosomiasis
[3]. However, studies indicate that PZQ-resistant laboratory strains can be isolated and clinical
isolates with increased PZQ resistance have been reported [4]. Therefore, it is a matter of time
before resistance fully evolves. In addition, PZQ is much less active against juvenile worms and
often results in incomplete cures [5–8] and its mechanism of action, including its biotransfor-
mation are not fully understood [3].
Biotransformation pathways play vital roles in providing essential molecules for cell survival
and to modify harmful molecules in order to facilitate their elimination. Xenobiotic biotrans-
formation occurs in three phases. Phase I metabolism involves the oxidative, reductive, or
hydrolytic transformations of xenobiotics, of which the most important are catalyzed by
CYP450 enzymes. In phase II transformation, metabolites undergo conjugation reactions with
endogenous compounds such as glutathione, glucuronic acid, amino acids, and sulfate in reac-
tions mainly catalyzed by glutathione S-transferases (GSTs), UDP-glucuronosyltransferases,
N-acetyltransferases, methyltransferases and sulfotransferases. Phase III transformations uti-
lize membrane-bound transport proteins, which carry modified molecules across membranes
for excretion [9]. There has been an extensive study of phase II metabolizing enzymes includ-
ing the glutathione S-transferase family in schistosomes. For example, the main GSTs identi-
fied in S.mansoni have been shown to bind to several commercially available anthelmintics
[10] and are currently important vaccine candidates [11]. Recently, a sulfotransferase was
implicated in the mechanism and selectivity of action of oxamniquine in schistosomes [12]. In
addition, Phase III biotransformation proteins, including the ATP-binding cassette (ABC)
transporters, have been identified and their role in praziquantel susceptibility, immunoregula-
tion within the host, parasite egg development and maturation, and translocation of important
signaling molecules such as glyco- and phospholipids is being studied [13]. However, very little
is known about phase I metabolizing CYP450 enzymes in schistosomes.
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CYP450s are heme-containing monooxygenases. In concert with NADPH CYP450 reduc-
tases, the heme group of CYP450s serves as a terminal oxidase, i.e., a source of electrons to split
molecular oxygen, with one oxygen atom added to the substrate and the other atom accepting
reducing equivalents from NADPH to form water [14]. Characterized CYP450 reductase pro-
teins are well conserved and occur as single copy genes in individual organisms. However, the
CYP450 proteins are quite diverse, with most organisms having multiple CYP450 genes
(Table 1) [9,15]. Analysis of the S.mansoni genome database has identified only one potential
CYP450 gene [16]. In a previous study, extracts of adult S.mansoni and S. haematobium were
shown to metabolize some typical CYP450 substrates and immunoblotting experiments with
an anti-rat CYP450 antibody had cross-reactivity with both S.mansoni and S. haematobium
homogenates with a specific band at ~50 kDa, well within typical CYP450 molecular weight
range [17].
In addition to biotransformation activities, CYP450 proteins are involved in the metabolism
of many essential endobiotic compounds. Synthesis of membrane sterols, cholesterol and
ergosterol depends on CYP450s as does synthesis and degradation of steroid hormones
[18,19]. Cellular levels of retinoic acid, the active metabolite of vitamin A, which is essential for
embryonic development, postnatal survival, and germ cell development, are regulated and
metabolized by several CYP450 proteins [18]. Other CYP450s are involved in the metabolism
of prostaglandins, prostacyclins, and leukotrienes [19], all derivatives of fatty acids and impor-
tant for cell signaling and immune response. In Caenorhabditis elegans CYP450 proteins are
thought to be involved in meiosis, egg polarization, and egg shell development [20].
In this study, we hypothesize that the single CYP450 gene present in schistosomes is essen-
tial for worm survival and that blocking its function would lead to worm death and/or interfer-
ence in parasite development. We used both genetic and pharmacological approaches to test
this hypothesis. Treating larval parasites with SmCYP450-specific double-stranded RNA led to
significant decreases in CYP450 mRNA and resulted in worm death. Screening a collection of
CYP450 inhibitors (Fig 1) we found that low micromolar concentrations of imidazole antifun-
gal CYP450 inhibitors had schistosomicidal activity against adult and larval worms and
blocked embryonic development in the egg. We conclude that SmCYP450 is essential for para-
site survival and egg development, and it is proposed as a novel target for antischistosomal
drug development, with miconazole analogs as starting points in drug discovery.
Materials and Methods
Ethics statement
In all of the experiments involving the use of animals, maintenance and use of these animals
were performed in accordance with protocols approved by the Institutional Animal Care and
Table 1. Comparison of the number of CYP450 and CYP450 reductase genes from different species
compiled from Nelson et al. [15]
Organism CYP450 CYP450 Reductase
Schistosoma mansoni 1 1
Schmidtea mediterranea 39 1
Human 57 1
Mus musculus 103 1
Gallus gallus 41 1
Danio rerio 81 1
Drosophila melanogaster 90 1
Caenorhabditis elegans 81 1
doi:10.1371/journal.pntd.0004279.t001
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Use Committee (IACUC) at Rush University Medical Center (IACUC number 14–080; DHHS
animal welfare assurance number A3120-01). Animals were euthanized with a lethal dose of
Nembutal.
Chemicals and reagents
CYP450 inhibitors (Fig 1) were purchased from Sigma Aldrich (miconazole, clotrimazole,
ketoconazole, posaconazole, triadimenol, sertaconazole, bifoconazole, econazole, butoconazole,
dafadine, fluconazole), Santa Cruz Biotechnology (piperonyl butoxide, tioconazole, fenticona-
zole, prochloraz, sulconazole, oxiconazole, anastrozole, letrozole, aminoglutethimide), and
Cayman Chemical Company (abiraterone acetate). Sulfaphenazole was synthesized according
to published procedures [21,22].
Experimental organisms
A Puerto Rican strain of S.mansonimaintained in Biomphalaria glabrata snails and the same
strain of S.mansonimaintained in NIH Swiss mice was supplied by the Biomedical Research
Institute (Rockville, Maryland, USA). All adult worms, schistosomula, and egg cultures were
incubated in Basch’s Media 169 [23]. Basal Medium Eagle was from Life Technologies; glucose
and fungizone were from Fisher Scientific; hypoxanthine, serotonin, insulin, hydrocortisone,
triiodothyronine were from Sigma Aldrich; MEM vitamins, Schneider’s Drosophila Medium,
and gentamicin were from Gibco; HEPES buffer fromMediatech, Inc.; penicillin/streptomycin
from Cellgro; and fetal bovine serum was from HyClone Laboratories, Inc.
Cercariae were shed from infected Biomphalaria glabrata snails and mechanically trans-
formed to schistosomula as described [24]. To collect liver-stage, juvenile parasites mice were
Fig 1. Chemical structures of CYP450 inhibitors used in this study.
doi:10.1371/journal.pntd.0004279.g001
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perfused 23 days post infection and to collect adult worms mice were perfused 6–7 weeks after
infection with Dulbecco’s modified Eagle’s medium (Gibco) using methods described previ-
ously [24]. Live worms were washed thoroughly with DMEM. Eggs were obtained from the liv-
ers of the mice 7 weeks post infection. Livers were placed in ice-cold PBS and stored at 4°C
overnight and processed the following day as described [24]. Parasite material was stored at
-80°C for later use in stage specific SmCYP450 mRNA quantitation.
Analysis of the SmCYP450 sequence and investigation of sequence
variation
The CYP450 open reading frame was amplified from adult mixed cDNA using P450_5' and
P450_3' (all primers listed in Table 2) and GoTaq Flexi DNA Polymerase (Promega). PCR
product was cloned into pCRII (Invitrogen) and plasmids were purified (Plasmid Mini Kit
(QIAGEN) and sequenced at the University of Illinois-Chicago Core Sequencing Center
(UIC). Alignment of the obtained open reading frame with the genome sequence was done
using the Needleman-Wunsch Global Sequence Alignment Tool (http://blast.ncbi.nlm.nih.
gov/Blast.cgi). Prediction of the molecular weight of the encoded protein was done at the Swiss
Institute of Bioinformatics Resource Portal (http://web.expasy.org/compute_pi/).
Internal Coordinate Mechanics (ICM) homology modeling tool (http://www.molsoft.com)
[25,26] was used to generate a CYP3050A1 model based on the CYP2C5 (PDB ID 1nr6) tem-
plate and the structure-superimposition-guided sequence alignments performed using the iter-
ative dynamic programming and superimposition steps implemented in the ICM Homology
Modeling module [27]. Alignments were further adjusted manually to preserve integrity of the
a-helices and b-sheets, patterns of positive (blue) and negative (red) charges, aromatic (purple)
and hydrophobic (green) functionalities, and finally, proline (ochre) and cysteine (yellow) side
chains. Global optimization was performed using the Biased Probability Monte Carlo (BPMC)
Table 2. List of primers used for PCR, RT-PCR and qRT-PCR.
Primer Sequence
T3 GCTCGAAATTAACCCTCACTAAAGGG
SK CGCTCTAGAACTAGTGGATC
SL AACCGTCACGGTTTTACTCTTGTGATTTGTTGCATG
P450_5' ATGGATACCTTTGAATTTTATG
P450_3' TTACTTCCATACATCGGTACG
CYP450-R1 CACCATAAGTTGCAACAACG
CYP450-R3 GTTGAGAAGCAGACACATCC
CYP450-revComF2 CTGACTATTGTGTACAGCATA
SmCYP450-For GTGGACAATTCTGTTGTCTA
SmCYP450-Rev CTCCAAACTGTACATCTCATC
T7-T3 TAATACGACTCACTATAGGGATTAACCCTCACTAAAGGGA
qPCR-p450-F TGCTGGTACTGACACCACGTCTTT
qPCR-p450-R GGAACTACACTAGCCCAACGATGA
qPCR-tubulin-F CACGAGCAGTTAAGCGTTGCAGAA
qPCR-tubulin-R TATTTGCCGTGACGAGGGTCACAT
CYP450-interF2 TATGCTGTACACAATAGTCAG
ORF_CYP450 Reverse TTAAATACTTGTTCTTCTATTTCC
GAPDH_S.mansoni FWD ATGTTCGTTGTTGGTGTGAATG
GAPDH_S.mansoni REV TTCCGTTTATGTCTGGAATGA
doi:10.1371/journal.pntd.0004279.t002
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conformational search combined with the electrostatic energy term [28]. Loop search and side
chain refinement was conducted for up to 100,000 iterations, which included full energy mini-
mization at each step, to result in a model with satisfactory local strain parameters [29].
To determine if a subset of CYP450 mRNAs was trans-spliced, the S.mansoni trans-spliced
leader sequence was used in PCR with either CYP450-R1 or CYP450-R3 specific internal prim-
ers (Table 2). A modified 5’ rapid amplification of cDNA ends (RACE) with Q5 DNA polymer-
ase (New England Biolabs) was done in a nested PCR using an adult cDNA library (kindly
provided by Dr. Philip LoVerde) as the template and vector primer T3 + gene-specific
CYP450-revComF2 in the first stage and the vector primer SK + gene-specific SmCYP450-Rev
(Table 2) for the second stage. The product of the second PCR was cloned into pCR4 (Invitro-
gen). To determine if the SmCYP450 mRNA is alternatively spliced, the complete ORF was
amplified using Q5 DNA polymerase from adult male, adult female, and egg cDNA (synthe-
sized as described below) with P450_5' and P450_3'. PCR products were cloned into pCR4.
Plasmid DNAs were isolated (GeneJET Plasmid Miniprep Kit, Thermo Scientific) and
sequenced at the UIC sequencing core.
RNA interference (RNAi)
Plasmid Construction. A 566 bp SmCYP450 sequence close to the N-terminal region of
the SmCYP450 gene was amplified using SmCYP450-For and SmCYP450-Rev and cloned into
a pCRII vector (Invitrogen) according to the manufacturer’s protocol. The sequence was veri-
fied through Sanger sequencing at the UIC sequencing core. A new primer (T7-T3) was
designed flanking the 566 bp sequence so that it included the full T7 promoter primer followed
by part of the T3 primer sequence. PCR was carried out using T7 and T7-T3 primers with Taq
DNA polymerase (Thermo Scientific) at 96°C 2 min, followed by 40 cycles at 94°C, 1 min;
48°C, 2 min; 72°C, 1.5 min; then 72°C, 7 min. The PCR product was run on a 1% agarose gel
containing ethidium bromide to verify the insert size. The PCR product was cut out from the
gel and cleaned with Gel Extraction kit (Qiagen) and the concentration determined.
CYP450 dsRNA Synthesis. Both a published method [30] using T7 RNA polymerase
(New England BioLabs) and the MEGAclear kit (Life Technologies) were used to synthesize
SmCYP450 dsRNA. In the first method, synthesis was carried out in a 100 μl reaction mix
using 100 μg/ml BSA (NEB), 500 μM each of rNTPs (NEB), 1 x RNA Pol reaction buffer (40
mM Tris-Cl, 6 mMMgCl2, 10 mM dithiothreitol), and 800 units/ml RNase inhibitor (NEB) at
40°C for 4.5 hours. The resultant product was treated with RNAase free DNase I (NEB) at 37°C
for 10 min and cleaned using Zymogen DNA-free RNA kit and eluted with DNase/RNase free
water, or the DNase I treated samples were precipitated in 75% DEPC treated ethanol and 4 M
LiCl and re-suspended in DEPC treated water. The concentration of the cleaned ssRNA was
determined using a Nanodrop spectrophotometer. Synthesis using the MEGAclear kit followed
manufacturer’s protocols with RNA products cleaned as described above. The RNAs were
annealed to form dsRNA by incubating at 75°C, 50°C, and 37°C for 3 min each, and the con-
centration was determined by Nanodrop spectrophotometry. A negative control dsRNA was
synthesized as described above from the ccdB and camR- bacterial gene insert of pJC53.2 plas-
mid obtained from Dr. James Collins (UIUC) [30].
RNAi Cultures. Freshly prepared schistosomula (300–400) were placed in each well con-
taining 1 ml Basch’s media in a 24-well plate and incubated overnight in a 37°C and 5% CO2.
The following day SmCYP450 dsRNA or control irrelevant dsRNA was added to each well to a
final concentration of 10 or 30 μg/ml. Treatments were done in duplicate. Over several days
worms were observed for dead (dark, granular appearance and non-motile) or alive (translu-
cent and motile) as described [31].
Schistosomamansoni CYP3050A1
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Inhibitor treatment
To determine the activity of CYP450 inhibitors, 10 worm pairs in 5 ml Basch’s media per well
in 6-well plates were cultured overnight at 37°C and 5% CO2 and the following day CYP450
inhibitors (Fig 1) were added to each well. The media were replenished every 48 hr with fresh
media and inhibitors. Dead worms were identified as those that showed no motility when
observed for several minutes. For larval worms, 300–400 freshly prepared schistosomula were
placed in each well in a 24-well plate containing 1 ml Basch’s Media and incubated overnight
at 37°C and 5% CO2. The following day compounds were added to each well and the parasites
observed for several days without changing the media or adding fresh compounds. Live and
dead parasites were classified as before.
To monitor the effects of miconazole on egg development we followed a recently published
method [32]. Freshly perfused adult worm pairs were incubated in Basch’s media overnight.
The following day worms were removed and miconazole (5 or 10 μM) or an equal volume of
DMSO was added to the eggs produced. Eggs were further incubated a total of 72 hr in the
presence of miconazole. Each group of treated eggs was then collected and centrifuged (500 x
g, 5 min) and the supernatant discarded. The egg pellets were each washed in excess PBS and
centrifuged. The eggs were then fixed in 100% methanol at room temperature for 10 min. After
removing the methanol the eggs were incubated in DAPI (4’6-diamidino-2-phenylindole)
Fluoromount-G (SouthernBiotech) overnight at 4°C for nuclear staining. Images were cap-
tured using Zeiss Axiovert Z1 imaging microscope and analyzed with AxioVision software LE
(release 4.8.2 SP3, 2013).
Combined inhibitor and RNA interference
To see if their activities had additive effects, schistosomula were treated with dsCYP450 RNA
at a concentration that alone did not kill schistosomula (10 μg/mL) and miconazole at concen-
trations that resulted in minimal killing (2.5 or 5 μM) or each alone. Schistosomula cultures
were set up as described above. A control experiment was set up with irrelevant dsRNA with
and without 5 μMmiconazole. Parasites were observed as described above.
Total RNA isolation and cDNA synthesis
Total RNA was isolated from frozen worm and egg samples using the TRIzol Reagent (Life
Technologies) per the manufacturer’s recommendation in a 2 ml Lysis Matrix Tubes (MP Bio-
medicals) containing 500 μl TRIzol reagent. Tubes were shaken three times for 20 seconds each
using a tissue homogenizer (FastPrep-24 5G Instrument, MP Biomedicals). The samples were
incubated on ice for 5 minutes in between each lysis process. After lysis, another 500 μl TRIzol
Reagent was added to each sample, mixed and incubated at room temperature for 5 min. The
resultant sample was spun at 13,000 x g for 1 min to pellet cellular debris. Following centrifuga-
tion, supernatants were transferred to a new 1.5 ml microfuge tube and extracted with chloro-
form/isopropanol according to the manufacturer’s instructions. The gelatinous, white RNA
precipitate obtained after the chloroform/isopropanol extraction was resuspended in DEPC
treated water in 75% ethanol and spun at 6500 x g for 5 min at 4°C. After centrifugation the
supernatant was removed and the RNA pellet briefly air-dried and re-suspended in DEPC-
treated water, heated briefly at 55°C quantified on a Nanodrop spectrophotometer. Total RNA
was used for cDNA synthesis (iScript, BIO-RAD) per the manufacturer’s recommendation.
The synthesized cDNA for each sample was quantified by Nanodrop spectrophotometry and
stored at -20°C.
Schistosomamansoni CYP3050A1
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004279 December 29, 2015 7 / 21
Quantitative RT-PCR (qPCR) and semi-quantitative RT-PCR
Primers used for qPCR are shown in Table 2. α–tubulin (GenBank accession M80214) was
used to normalize the results. The reactions were each carried out in a 20 μl reaction using
ROX Passive Reference Dye (Bio-Rad) according to the manufacturer’s protocol. The amplifi-
cation was monitored in a 7900HT Fast Real-Time PCRMachine (Applied Biosystems) under
the following cycle conditions: (stage 1, 95°C 30 sec, stage 2, 95°C 5 sec, 60 C 30 sec) x 50, plus
a one cycle dissociation curve. Fold differences were calculated using the 2-ΔΔCT as described
[33] with α–tubulin transcript levels serving as the internal standard. Reactions were done in
triplicate. Semi-quantitative RT-PCR was used to assess the relative abundance of SmCYP450
mRNA after RNAi silencing using Platinum Taq DNA polymerase (Life Technologies. Glycer-
aldehyde 3-phosphate dehydrogenase (GenBank accession M92359) was used as a control gene
(primers GAPDH_S.mansoni FWD and GAPDH_S.mansoni REV) and SmCYP450 cDNA
was amplified with primers CYP450-interF2 and ORF_CYP450 Reverse.
Results
The SmCYP450 coding sequence is similar to CYP450 proteins in other
organisms
Cloning and sequence analysis shows that the SmCYP450 coding sequence is 1452 base pairs
encoding a protein of 483 amino acids with a predicted molecular weight of 55.28 kDa. The
family assignment as CYP3050A1 was made by Dr. David R. Nelson according to the CYP450
nomenclature [34,35]. The sequence was found to be longer than the sequence reported in
GeneBank (Smp_156400, 1245 base pairs,) due to a miscalled junction of the 5th intron/6th
exon during genome annotation. The sequence obtained was submitted to GenBank with the
accession number KT072747. The gene is composed of 7 exons and 6 introns spanning 15,378
base pairs (not including 5’ and 3’ noncoding sequences). Sequence analysis shows it to be
comparable to CYP450 proteins from other organisms. The signature heme-binding motif
[14,36], [FW]-[SGNH]-x-[GD]-{F}-[RKHPT]-{P}-C-[LIVMFAP]-[GAD], is present (the
bold, underlined residues are present in SmCYP450) (Fig 2). The ‘P450-signature’ sequence,
[AG]-G-X-[DE]-T-[TS], which forms a channel for electron transfer [36], is also present in the
SmCYP450 peptide. The protein has an N-terminal membrane spanning region followed by
the poly-proline domain, which is important for protein folding and structural integrity [37].
The turns by the poly-proline region provide a junction between the transmembrane region
and the main catalytic domain typical for most CYP450 proteins [37]. The organization of the
predicted secondary structure of the SmCYP450 protein sequence follows other CYP450 pro-
teins, beginning from helix A in the N-terminal region of the protein sequence and ending
with helix L, which contains the heme-binding sequence (Fig 2). Likewise, with the exception
of the absence of the J and J’ helices, the tertiary structure of SmCYP450 protein is predicted to
be similar to known CYP450 proteins (Fig 3).
There is a single CYP450 protein in S.mansoni
It is possible that a diversity of CYP450 proteins or alternative subcellular targeting of
SmCYP450 results from alternative splicing or post-transcriptional modifications of the
mRNA produced from the single S.mansoni CYP450 gene. This was addressed by analyzing
cDNAs from a variety of developmental stages and by using modified 5’RACE and PCR with
the schistosome spliced leader sequence to search for multiplicity of CYP450 mRNAs. We ana-
lyzed 33 clones from adult female worm cDNA, 23 clones from adult male worm cDNA, 11
clones from egg cDNA, and 28 clones generated by 5’ RACE and all sequences were identical.
Schistosomamansoni CYP3050A1
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Fig 2. Comparison of SchistosomamansoniCYP450 protein (Sman) with CYP450 proteins from other species.Multiple alignment of CYP450
proteins from S.mansoni (csm305A); rabbit CYP450 2C5 (1nr6_a); human CYP450 2C9 (1r9o_a); human CYP450 2C19 (4gqs_a); human CYP450 1A1
(4i8v_a); and human CYP450 2b6 (4rrt_a). The residues are shown in one letter code and colored by type: red- negatively charged, blue—positively
charged, yellow—Cys, green—hydrophobic, cyan—Gly, ochre—Pro, purple—aromatic. The residues are shown in brighter colors for conserved positions.
The ‘P450-signature’ sequence, which forms a channel for electron transfer, and the CYP450 consensus motif responsible for heme-binding and interaction
with molecular oxygen and the relevant substrates are boxed. Predicted helices in the secondary structure based on homology modelling of SmCYP450 are
indicated by the bold letters A-L based on rabbit CYP450 2C5 [38].
doi:10.1371/journal.pntd.0004279.g002
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Therefore, we found no evidence for alternative splicing or other sequence variations. PCR
with the spliced leader sequence and two different internal CYP450-specific primers resulted
in no PCR products; therefore, the SmCYP450 mRNA does not appear to be trans-spliced.
Therefore, it appears that the SmCYP450 gene encodes a single CYP450 protein.
S.mansoni CYP450 is differentially expressed during parasite
development in the mammalian host
Using qRT-PCR we found that SmCYP450 mRNA was present at all developmental stages
investigated and that it is differentially present during development (Fig 4). Eggs, the larval
stages of development (cercariae and schistosomula) and adult female worms had higher
mRNA levels than adult male worms. Liver stage parasites had the lowest SmCYP450 mRNA
expression levels, about 50% that of adult males.
Fig 3. Structural modeling of S.mansoniCYP450 (CYP3050A1) and comparison to the structure
determined for rabbit CYP450 2C5 (1nr6_a) [38]. The heme is shown is each model as a space-filling
projection. The J and J’ helices in rabbit CYP450 2C5, which are absent in S.mansoni CYP450, are
highlighted in yellow.
doi:10.1371/journal.pntd.0004279.g003
Fig 4. CYP450messenger RNA abundance during the lifecycle of Schistosomamansoni.Whole RNA
was extracted from different stages of S.mansoni (cercariae, 1-day old schistosomula; juvenile liver worms
(23 days post infection), adult males (49 days post infection), adult females (49 days post infection) and eggs)
using TRIzol reagent and chloroform/ethanol extraction protocol. cDNA was synthesized from whole RNA
and used for qRT-PCR, with reactions done in triplicate. Adult males (= 1) were used as calibrator stage and
mRNA abundance was normalized to α-tubulin. Error bars indicate standard error of the mean with n 3
biological replicates. Numbers indicate fold change relative to adult males and all values are significantly
different from adult males; p < 0.05; student t-test. The results indicate that S.mansoniCYP450 is expressed
in all stages investigated and that its expression is developmentally regulated.
doi:10.1371/journal.pntd.0004279.g004
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S.mansoni CYP450 dsRNA treatment leads to schistosomula death
To determine if SmCYP450 is essential for schistosomula survival we used RNAi to silence
SmCYP450 expression. Treating worms with 10 μg/mL or 30 μg/mL SmCYP450 specific
dsRNA for two or three days resulted in a dose-dependent reduction in SmCYP450 message
(Fig 5A). No change was seen in SmCYP450 mRNA after treatment with 30 μg/mL irrelevant
dsRNA or in GAPDHmRNA abundance after treatment with either dsRNA (Fig 5A). Treat-
ment with 30 μg/mL SmCYP450 specific dsRNA resulted in 80% schistosomula survival by day
3, 40% survival by day 5, and 15% survival by day 7. In contrast, 95% and 94.5% of schistoso-
mula were alive on day 7 after treatment with 30 μg/mL irrelevant dsRNA or 10 μg/mL
SmCYP450 specific dsRNA, respectively (Fig 5B).
The imidazole subgroup of azole antifungal CYP450 inhibitors is active
against S.mansoni
CYP450 enzymes are inhibited by numerous anti-infective and anticancer agents. We next
asked if clinically relevant CYP450 inhibitors (Fig 1) affected parasite survival. Several antifun-
gal imidazoles (miconazole, clotrimazole, ketoconazole) but not closely related triazole antifun-
gals (fluconazole, posaconazole and triadimenol) were active against both larval and adult
Fig 5. Effect of silencing Schistosomamansoni CYP450 in cultured larval worms. Freshly prepared
schistosomula (300–400) were placed in each well containing 1 ml Basch’s Media in a 24-well plate and
overnight in a 37°C with 5% CO2. The following day schistosomula were treated with 10 or 30 μg/ml S.
mansoniCYP450 dsRNA or 30 μg/ml negative control dsRNA. Over several days worms were observed for
dead (dark, granular appearance) or alive (translucent). (A) mRNA expression patterns in schistosomula
treated with S.mansoniCYP450 specific dsRNA or negative control dsRNA control after 3 days of treatment
(Experiments 1 and 2) or 2 days treatment (Experiment 3). The control gene for cDNA input is S.mansoni
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). C, schistosomula treated with 30 μg/mL irrelevant
dsRNA; 10, schistosomula treated with 10 μg/mL SmCYP450 dsRNA; 30, schistosomula treated with 30 μg/
mL SmCYP450 dsRNA. (B) Effect of S.mansoniCYP450 dsRNA on schistosomula survival in cultures with
30 μg/mL negative control dsRNA (black square), 10 μg/mL S.mansoniCYP450-specific ds RNA (open
triangle), and 30 μg/mL S.mansoniCYP450-specific ds RNA (black triangle). Treatments were done in
triplicate and repeated 3 times. Error bars indicate standard error of the mean; *, p < 0.05; student t-test.
doi:10.1371/journal.pntd.0004279.g005
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worms (Fig 6A and 6B and Table 3). Miconazole, clotrimazole, and ketoconazole had ED50
(Effective Dose producing 50% worm death) values of 10 μM, 20 μM, and 40 μM, after 5 day
treatments against adult worms and 12.5 μM, 27.5 μM, and 30 μM after 2 day treatments
against schistosomula, respectively. Other CYP450 inhibitors, such as prochloraz, sulfaphena-
zole, piperonyl butoxide, dafadine, letrozole, aminoglutethimide, abiraterone acetate, and ana-
strozole had no significant schistosomicidal activity against either larval or adult worms
(Table 3). Expansion of the anti-fungal imidazole series was done to generate preliminary
structure activity relationships of this compound series. Our studies revealed that imidazoles
that retained the 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethan-1-ol moiety of miconazole
had significant schistosomicidal activity against both larval and adult worms, while those
which lacked this moiety had much reduced or no schistosomicidal activity (Table 3, Fig 6C).
Miconazole targets SmCYP450
Does the potent schistosomicidal activity of miconazole act through inhibition of worm
CYP450 or does it have other targets in the worm? To address this question we tested low
doses of miconazole against worms treated with 10 μg/mL dsRNA CYP450, which caused no
significant worm death itself. While 5 μMmiconazole alone resulted in 80% survival after 6
days, combinations of 5 μMmiconazole and 10 μg/mL SmCYP450-specific dsRNA resulted in
60% survival (p = 0.0042). Combining 2.5 μMmiconazole (90% survival alone) and 10 μg/mL
Fig 6. Activity of anti-fungal imidazole CYP450 inhibitors on larval and adult Schistosomamansoni
worms. Survival of schistosomula (A) after 2 d culture and adult worms (B) after 5 d culture for miconazole
(black diamond), clotrimazole (black square), and ketoconazole (black triangle). (C) In house SAR on known
miconazole analogs against adult worms. Numbers in the parenthesis are survival (%) of adult worms on day
7 in 10 μM of respective compound.
doi:10.1371/journal.pntd.0004279.g006
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Table 3. Results with selected cytochrome P450 inhibitors used in this study.
Entry Compound Survival at 7 days (%) Function and CYP450 class inhibited
Adult Schistosomula
5 μM 10 μM 5 μM 10 μM
1 Miconazole 57 10 72 22 antifungal CYP51
2 Sertaconazole 95 15 65 6
3 Sulconazole 100 50 90 56
4 Fenticonazole 75 50 92 79
5 Econazole 100 55 87 66
6 Oxiconazole 100 60 89 71
7 Tioconazole 100 85 86 82
8 Bifoconazole 100 100 80 79
9 Butoconazole 100 80 77 60
10 Clotrimazole n.d.1 100 97 90
11 Ketoconazole n.d. 100 98 97
12 Fluconazole 100 100 98 94
13 Posaconazole 100 100 94 88
14 Triadimenol 100 100 99 99
15 Prochloraz 100 100 94 82
16 Sulfaphenazole 100 100 99 93 antibacterial CYP2C9
17 Piperonyl butoxide 100 100 100 100 pesticide CYP6D1
18 Abiraterone acetate 100 100 100 100 prostate cancer CYP17A1
19 Anastrozole 100 100 100 100 breast cancer CYP19A1
20 Letrozole 100 100 100 100
21 Aminoglutethimide 100 100 100 100
22 Dafadine 100 100 100 100 CYP27A1
1n.d., not determined.
doi:10.1371/journal.pntd.0004279.t003
Fig 7. Combinations of miconazole and RNAi have increased killing activity, suggesting that they function through inhibition of the same target.
(A) Schistosomula cultured with 10 μg/ml S.mansoniCYP450 dsRNA (black diamond); 2.5 μMmiconazole (open circle); or 10 μg/ml S.mansoniCYP450
dsRNA and 2.5 μMmiconazole (black circle). (B) Schistosomula cultured with 10 μg/ml S.mansoni CYP450 dsRNA (black diamond); 5 μMmiconazole
(black square); 5 μMmiconazole plus 30 μg/ml irrelevant dsRNA and 5 μMmiconazole (open circle); or 5 μMmiconazole plus 10 μg/ml S.mansoniCYP450
dsRNA and 5 μMmiconazole (black circle). All experiments were done in triplicate. Error bars indicate standard error of mean; *, p < 0.05; student t-test).
doi:10.1371/journal.pntd.0004279.g007
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SmCYP450-specific dsRNA resulted in 75% survival (p = 0.007) (Fig 7A). Addition of 30 μg/
mL irrelevant dsRNA treatment had no effect on killing by 5 μMmiconazole (Fig 7B). These
results strongly suggest that miconazole schistosomicidal activity is specific for SmCYP450.
Miconazole treatment results in impaired schistosome egg development
To determine if miconazole interferes with egg development and maturation we treated eggs
deposited by freshly perfused adult worm pairs with miconazole and monitored embryo devel-
opment using a recently described method [32,39]. Egg development was scored based on the
number and arrangement of cell nuclei (Fig 8A). Our results indicate that there is a general
interference of egg development and accumulation of early embryonic stages (I, II and III) and
decrease in late stage embryos (IV and V) in the miconazole treatments compared to the
DMSO controls. Only 30% (18/62) of eggs treated with 5 μMmiconazole and 18% (10/56)
treated with 10 μMmiconazole reached the latter stages of egg development (stages IV and V)
compared to 64% (35/55) in DMSO control (Fig 8B). These results indicate that miconazole
affects embryonic development.
Fig 8. Effect of miconazole on egg development. (A) Example of egg development scoring scheme. Upper
panel shows fluorescent images of eggs representative of each developmental stage scored; the bottom
panel shows brightfield images of the same eggs. (B) Scoring of egg development in cultured eggs treated
with 0, 5, or 10 μMmiconazole. The percentage of eggs scored at developmental stages I-III (black bars) and
eggs scored at developmental stages IV-V (gray bars) are indicated. For 0 μMmiconazole, n = 55 eggs
scored; for 5 μMmiconazole, n = 56 eggs scored; for 10 μMmiconazole, n = 62 eggs scored.
doi:10.1371/journal.pntd.0004279.g008
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Discussion
Because schistosomiasis control relies on a single drug and there is field evidence for the evolu-
tion of drug resistance [3,4], there is an urgent need to identify new, druggable worm targets.
In this study we present the first detailed characterization of the CYP450 from S.mansoni and
provide strong evidence that it is an essential and druggable target in the worm.
The SmCYP450 exists as a single copy gene in the S.mansoni genome [16]. This is in stark
contrast to humans, which have 57 genes and alternative splicing and genetic variations that
can lead to the production of many more distinct protein species [40,41], and to the free-living
flatworm Schmidtea mediterranea, which has at least 39 CYP450 genes [15]. The loss of
CYP450 family members in parasitic helminths has been noted previously [42]. However, the
fact that parasitic flatworms have retained one CYP450 signifies that it plays an important and
perhaps essential function. We add here that in S.mansoni there appears to be no post-tran-
scriptional modifications (alternative or trans-splicing, RNA editing) to the mRNA. Therefore,
it is likely that a single protein product is produced from the SmCYP450 gene. Since there was
no evidence for alternative splicing to insert different leader sequences at the N-terminus, the
protein product is likely only targeted to the endoplasmic reticulum.
The predicted protein has generally low sequence identity with the other CYP450s; the high-
est identity to human CYP450 proteins is 22% to CYP2C9. Importantly, the CYP450 consensus
motif responsible for heme-binding and interaction with molecular oxygen and the relevant
substrates and the ‘P450-signature’ sequence are conserved in the SmCYP450 protein
sequence. Curiously, SmCYP450 lacks a number of motifs found in many characterized
CYP450. The majority of CYP450s contain an ‘EXXR motif’ in helix K. The glutamic acid and
arginine residues form a charge pair with a third amino acid more distant in the meander
region. This is frequently an arginine in the so-called ‘PERF motif’. Putative functions of the
EXXR motif and PERF motif may be to associate heme with the newly synthesized CYP450
polypeptide and/or to maintain the CYP450 tertiary architecture [43]. This is key to the struc-
tural fold of CYP450s and previous studies in which mutagenesis directed at the side-chains of
glutamic acid or arginine in the EXXR motif or at the invariant cysteine in the L-helix resulted
in completely inactive and misfolded proteins [44]. However, these motifs are not present in
CYP450s from parasitic Trematodes (e.g., Schistosoma, Clonorchis sinensis) and Cestodes (e.g.,
Echinococcus multilocularis) [42]. Their absence is not without precedent as the EXXR motif is
also absent in most members of a CYP157 subfamily in Streptomyces spp [45]. The Trematode
CYP450 proteins also lack the J and J’ helices, which occur to the N-terminal side of and
include the EXXR motif. How these differences affect protein structure and function remains
to be determined.
CYP450s function in an electron transport chain in which electrons are passed from
NADPH through a flavoenzyme either directly to the CYP450 heme or indirectly through cyto-
chrome b5 or ferredoxin. In the endoplasmic reticulum, the flavoenzyme is NADPH CPY450
reductase. Additional partners of CYP450s in the endoplasmic reticulum include cytochrome
b5 and cytochrome b5 reductase. In mammals, ferredoxin reductase and ferredoxins (also
known as adrenodoxin reductase and adrenodoxins) are found in the mitochondria and are
involved in steroid hormone synthesis mediated by CYP450s. The S.mansoni genome contains
one CYP450 reductase, two cytochrome b5s, two cytochrome b5 reductases, one ferredoxin
reductase, and two ferredoxins with potential to support SmCYP450 activity. Previous studies
in schistosomes have found that ferredoxin reductase is mitochondrial and likely functions
there in redox defenses [46,47]. Since we currently have no evidence for mitochondrial target-
ing of SmCYP450 protein, it is not likely that it functions in concert with ferredoxin reductase/
ferredoxins.
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Unlike the only previously characterized trematode CYP450, which showed highest expres-
sion in adult hermaphrodites [42], SmCYP450 is expressed at the highest levels in larval and
egg stages. It is important to note that the developmental cycles and tissue locations of these
organisms are significantly different. After active host localization and penetration, S.mansoni
has extensive interactions with host skin, lungs, liver, and vascular epithelia, while Opisthorchis
worms reside in the bilary ducts after excysting from metacercariae in the duodenum. As
sequence identity between S.mansoni and O. felineus CYP450 proteins is only 37% it is quite
possible that CYP450s have different functions in the worms.
The function of the SmCYP450 is not yet known. Different development stages may require
different CYP450 metabolites and/or experience different immunological stresses. For instance
larval parasites penetrate the skin of human host and begin migration through the skin and
other tissue and may encounter different stress and immunological responses than adult
worms in the mesenteric system. Larval schistosomes synthesize and secrete eicosanoids [48–
53], which are signaling molecules derived from arachidonic acid, some of which are produced
by CYP450s. The eicosanoids produced by schistosomes may down modulate host immune
function [54,55]. Eicosanoids produced by adult worms may control other functions such as
vasodilator activity, and/or vasoconstrictive action [55].
Other potential functions of SmCYP450 are in the metabolism of cholesterol and steroid
hormones. Adult worms have been shown to convert cholesterol into several metabolites
including pregnenolone, the first committed metabolite in steroid hormone biosynthesis
[56,57]. Male worms transfer cholesterol and uncharacterized cholesterol metabolites to female
worms [56] and synthetic steroids have been shown to affect worm egg production in vivo [56].
More recently, a catechol-estrogen conjugate (downstream products of CYP450 metabolism of
estradiol and estrone), which has anti-estrogen affects, was identified in schistosome worm
extracts and in the serum of infected humans [58]. Retinoic acid is essential for embryonic
development in all metazoan organisms investigated, including free-living flatworms [59]. Ret-
inoic acid activity is controlled through its tightly regulated synthesis from vitamin A (all-trans
retinol) in a 2-step process by retinol dehydrogenases to all-trans retinal and by retinaldehyde
dehydrogenases to all-trans-retinoic acid and is terminated via its breakdown by CYP450s
[18,60]. Although retinoic acid signaling or metabolism in schistosomes is largely unknown,
they have enzymes involved in retinoic acid metabolism (10 retinol dehydrogenases and 2 reti-
naldehyde dehydrogenases) and nuclear receptors related to retinoic acid receptors [61–64].
Ecdysteroids are hormones involved in insect molting and development and CYP450s are
involved in their synthesis and transformation from farnesyl diphosphate and cholesterol.
Ecdysteroids have been detected in schistosomes and their levels shown to vary during devel-
opment [65,66]. S.mansoni synthesizes ecdysone and 20-OH ecdysone, which were shown to
be potent stimulators of growth and vitellogenesis [67]. β-Ecdysterone was found to be effective
in stimulating host location activities in S.mansonimiracidia [68]. Worms have two nuclear
receptors related to insect ecdysone receptors, but their function in ecdysteroid signaling has
not been determined [69,70]. Identification of the function of SmCYP450 will be targeted in
future studies.
Our findings indicate S.mansoni has a single CYP450 protein, with highest sequence iden-
tity to human CYP450s CYP2C9 and CYP1A1. In order to compare the differences between S.
mansoni CYP450 and human CYP450s we tested several different classes of CYP450 inhibitors.
Although miconazole and structurally related imidazoles had schistosomicidal activity against
adult and larval worms, other CYP450 inhibitors did not. These observations gave rise to an
early exploration to investigate the structure-activity-relationships (SAR) of imidazole class of
compounds, especially miconazole analogs (Fig 6C). Miconazole analogs were obtained by
substituting the (2,4-dichlorophenyl)methanol moiety with different aryl groups.
Schistosomamansoni CYP3050A1
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004279 December 29, 2015 16 / 21
Sertaconazole, which results from substitution with a (7-chlorobenzo[b]thiophen-2-yl) metha-
nol group, was equipotent to miconazole against adult and larval worms. Replacement with
(4-chlorophenyl) methanol group results in econazole. Replacement of the oxygen by a sulfur
in the econazole led to sulconazole. Modification of the econazole by substitution of a phe-
nylthio group for the 4-chloro led to fenticonazole. Replacement with an oxime moiety into the
miconazole gave oxiconazole. Econazole, sulconazole, fenticonazole and oxiconazole were less
potent than miconazole. Substitution with (2-chlorothiophen-3-yl) methanol moiety results
tioconazole, which is much less active. Our results indicate that miconazole constitutes a prom-
ising scaffold for targeting schistosome worms. Evidence that schistosomicidal activity of
miconazole and analogs resides in the 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethan-1-ol
moiety of miconazole suggests routes to improved activity by rational drug design in future
studies.
Miconazole had previously been included in a medium throughput phenotypic screen
against schistosomula in an effort to repurpose approved drugs [71]. In, this study, compounds
were screened at 1 μM against schistosomula and miconazole was found to be inactive, which
is consistent with our results. However, for our screening purposes we tested compounds at
higher concentrations and therefore, identified the schistosomicidal activity of this class of
compounds. Although the concentrations required for worm killing activity in vitromay not
be attained in vivo due to low biological availability, improved pharmacological properties can
be incorporated into miconazole analogs to overcome these limitations. Our results indicate
that the schistosomicidal activity of miconazole is due to inhibition of SmCYP450. Low con-
centrations of miconazole alone resulted in low schistosomicidal activity and partial reduction
of SmCYP450 mRNA alone resulted in no larval worm death. However, combination treat-
ments produced more than an additive response: 10% death in 2.5 μMmiconazole alone
increased to 20% with partial mRNA silencing and 20% death in 5 μMmiconazole alone
increased to 40% with partial mRNA silencing. The simplest explanation for this effect is that
partial mRNA silencing results in decreases in SmCYP450 protein, which although it is not
lethal to the worms itself, results in increased activity of miconazole due to a reduction in its
protein target abundance. This strongly suggests that both SmCYP450 dsRNA and miconazole
target the same pathway.
In schistosomes, egg development is a multi-stage process. Within the host mesentery and
vasculature, a mature female releases approximately 300 encapsulated embryos (pre-mature
eggs) per day [72,73]. Prior to that and within the mature female the early development of eggs
occurs in several pre-zygotic and post zygotic stages [74]. Using methods recently developed to
facilitate monitoring egg development [32,38] we investigated the effect of miconazole on egg
development and maturation. Treatment with miconazole resulted in a dose-dependent
impairment of ex vivo egg development, with most miconazole-treated eggs remaining at the
early stages of embryonic development (Stages I-III) compared to control treatments, in which
most eggs reached later stages of embryonic development (stages IV and V). CYP450 proteins
are known to be involved in egg development in C. elegans, with CYP31A2 and CYP31A3
essential for the production of lipids required for egg shell development [20]. In addition, reti-
noic acid is essential for embryonic development in all metazoan organisms investigated,
including free-living flatworms, and as indicated above, retinoic acid metabolism is mediated
by CYP450 proteins. Inhibition of retinoic metabolism by miconazole could interfere with
embryogenesis and egg development. There has not been a direct identification of SmCYP450
protein in eggs [75]. The newly oviposited egg is not fully formed and undergoes embryonic
and subshell envelope development [76]. It is not known if SmCYP450 functions in embryonic
or subshell envelope development or both, but our work shows for the first time that micona-
zole can block egg development.
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Schistosomiasis remains a challenging disease to people living in endemic areas. In spite of
many years of praziquantel use, the prevalence of infection remains high. The specter of evolv-
ing resistance to praziquantel, the only drug available for disease treatment, calls for the identi-
fication of new protein targets, the discovery of lead compounds and the development of new
drugs for the treatment of the disease. The S.mansoni CYP450 exists as a single gene in the par-
asite genome. Our work shows that it is essential for parasite survival and could be an ideal
drug target. In addition, select anti-fungal azoles could be promising starting points for future
studies towards identifying new therapies for schistosomiasis.
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